Why do many of the industry’s current dogmas and assumptions need to be replaced?
MV. Simply put, the current model does not address the need of a rapidly changing and growing patient pool globally in an affordable way. Extrapolations into the future only further emphasise this problem. Many diseases still do not have treatments or cures. Innovation is not just finding a new class of drugs, it is also innovating your operational practices which, again, other industries have been driven to do years ago. The current financial turmoil will greatly speed up this process as nobody can afford the luxury to continue with processes that are unnecessarily wasteful. NGP. On the positive side, how can companies take advantage of the opportunity to manufacture at low cost in international locations, such as India? What particular advantages do countries such as India offer in pharmaceutical R&D? MV. An obvious solution is to produce in a country such as India and increasingly this is now being implemented. Investment levels are at least 50% lower compared to the West, as are pe
